CI

At a glance

ClinicalIndex Comparison Record
Phase 2Not Yet Recruiting· 72 target
Drug / intervention
JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06781125
NCT06781125Phase 2Not Yet Recruiting
CompareCT.gov

A Phase I/II Clinical Trial to Evaluate the Safety and Tolerability of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody IV Infusion in Patients With Malignant Solid Tumors

Immorna Biotherapeutics, Inc.·interventional·Posted Jan 17, 2025·Updated Mar 24, 2026

In Brief

A Phase 2 clinical trial evaluating JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion for Malignant Solid Tumors. Not yet recruiting, targeting 72 participants.

Detailed Summary

This is an open-label, dose-escalation and dose-expansion Phase I /II clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with malignant solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Solid Tumors
Countries--
Collaborators--

Timeline

Phase 2Not Yet Recruiting
2025202620272028
First PostedJan 17, 2025
Enrollment StartMar 18, 2026
Primary CompletionMar 30, 2028
Study CompletionJun 30, 2028
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 1.5 years agoPrimary completion in 1.7 years

Interventions

JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusiondrug

JCXH-211:Tumor lesions are selected for intratumoral injection, and target or non-target lesions can be selected. The number of lesions selected for injection will be at the investigator 's discretion based on the patient' s general condition and tolerability . Anti-PD-1 antibody:Dosage and administration according to the instructions.